Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3) > Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):269-76

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  AUTOIMMUNE BULLOUS DISEASES 

Giornale Italiano di Dermatologia e Venereologia 2012 June;147(3):269-76

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Rituximab for autoimmune blistering diseases: recent studies, new insights

Lunardon L., Payne A. S.

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA


PDF


Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.

top of page